* Eledon Pharmaceuticals Inc ELDN.OQ reported a quarterly
adjusted loss of 69 cents per share for the quarter ended in
March. The mean expectation of four analysts for the quarter was
for a loss of 68 cents per share.
* Reported revenue was zero; analysts expected zero.
* Eledon Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 69 cents.
* The mean earnings estimate of analysts had fallen by
about 23.2%
in the last three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* Eledon Pharmaceuticals Inc shares had fallen by 40.6% this
quarter and lost 46.9% so far this year.
* The company reported a quarterly loss of $9.86 million.
* Wall Street's median 12-month price target for Eledon
Pharmaceuticals Inc is $25.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated May 12 at 09:54 p.m. All
figures in US dollars unless otherwise stated